Chen-hong Ding

415 Fengyang Road
Shanghai, 200003, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Inhibition of Acetylation Activity of p300/CBP Ameliorates Hepatic Steatosis Through Downregulation of ACSL4.

Inhibition of Acetylation Activity of p300/CBP Ameliorates Hepatic Steatosis Through Downregulation of ACSL4.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: September 30, 2025

Rifaximin ameliorates cirrhotic portal hypertension through suppression of microbiome-derived deoxycholic acid.

Rifaximin ameliorates cirrhotic portal hypertension through suppression of microbiome-derived deoxycholic acid.

Journal: Journal of hepatology

Published: July 28, 2025

SOX9 promotes hepatocyte proliferation via upregulating TGF-α expression during liver regeneration.

SOX9 promotes hepatocyte proliferation via upregulating TGF-α expression during liver regeneration.

Journal: Hepatology international

Published: June 04, 2025

Endothelial Tgfbr2 Deficiency Ameliorate Liver Fibrosis Through Regulating Angiocrine Signalling and Macrophage Accumulation.

Endothelial Tgfbr2 Deficiency Ameliorate Liver Fibrosis Through Regulating Angiocrine Signalling and Macrophage Accumulation.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: January 07, 2025

Differentiation therapy with hepatocyte nuclear factor 4α for patients with hepatocellular carcinoma.

Differentiation therapy with hepatocyte nuclear factor 4α for patients with hepatocellular carcinoma.

Journal: Cell research

Published: December 22, 2024

PRMT3 drives PD-L1-mediated immune escape through activating PDHK1-regulated glycolysis in hepatocellular carcinoma.

PRMT3 drives PD-L1-mediated immune escape through activating PDHK1-regulated glycolysis in hepatocellular carcinoma.

Journal: Cell death & disease

Published: October 24, 2024

Cell-permeated peptide P-T3H2 inhibits malignancy on hepatocellular carcinoma through stabilizing HNF4α protein.

Cell-permeated peptide P-T3H2 inhibits malignancy on hepatocellular carcinoma through stabilizing HNF4α protein.

Journal: Discover oncology

Published: August 06, 2024

Positive feedback between arginine methylation of YAP and methionine transporter SLC43A2 drives anticancer drug resistance.

Positive feedback between arginine methylation of YAP and methionine transporter SLC43A2 drives anticancer drug resistance.

Journal: Nature communications

Published: April 25, 2024

Tripartite motif 8 promotes the progression of hepatocellular carcinoma via mediating ubiquitination of HNF1α.

Tripartite motif 8 promotes the progression of hepatocellular carcinoma via mediating ubiquitination of HNF1α.

Journal: Cell death & disease

Published: August 23, 2023

SRY-Box transcription factor 9 triggers YAP nuclear entry via direct interaction in tumors.

SRY-Box transcription factor 9 triggers YAP nuclear entry via direct interaction in tumors.

Journal: Signal transduction and targeted therapy

Published: August 21, 2023

TRIB3-TRIM8 complex drives NAFLD progression by regulating HNF4α stability.

TRIB3-TRIM8 complex drives NAFLD progression by regulating HNF4α stability.

Journal: Journal of hepatology

Published: July 11, 2023

miR-541 is associated with the prognosis of liver cirrhosis and directly targets JAG2 to inhibit the activation of hepatic stellate cells.

miR-541 is associated with the prognosis of liver cirrhosis and directly targets JAG2 to inhibit the activation of hepatic stellate cells.

Journal: BMC gastroenterology

Published: June 28, 2023

Showing 1-12 of 20

Last Updated: 09/26/2026